First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT
SYDNEY, May 29, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with...
A NEW HOPE FOR PATIENTS SUFFERING FROM POTENTIALLY FATAL RARE HEART DISEASE: NUHCS IS FIRST IN ASIA TO RECRUIT PATIENTS FOR LANDMARK GENE EDITING CLINICAL TRIAL
The international study explores gene editing therapy to stop the production of proteins causing the disease in ATTR-CM patients SINGAPORE, May 14, 2025 /PRNewswire/ -- While receiving treatment for a car accident ten years ago, Mr Chua learnt that...
EpicQuest Education Enters into Key Agreement as Catalyst for Recruiting from Africa and the Middle East
The New Recruiting Initiative has the Potential to Bring 525 Students from these Regions into Davis University over the Term of the Agreement MIDDLETOWN, Ohio, May 7, 2025 /PRNewswire/ -- EpicQuest Education Group International Limited (NASDAQ:...
Canada Leads: Canada's No. 1 Hospital Announces Strategy to Attract World's Most Promising Scientists, Drive Health Innovation and Economic Growth
TORONTO, April 8, 2025 /PRNewswire/ -- In a bold move to position Canada as the ultimate destination for the brightest minds in medical research, whose work will help build our future economy, University Health Network (UHN) is unveiling the...